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1726-4The benefits and risks of proton pump inhibitor therapyProton pump inhibitors (PPIs) have become one of the most
commonly used types of medications worldwide. They can be
effective in treating peptic ulcer disease (PUD), peptic ulcer
bleeding (PUB), as well as nonerosive and erosive esophagitis
via gastric acid inhibition. PPIs are also a fundamental ele-
ment of combination therapy for Helicobacter pylori erad-
ication. For prophylaxis, PPIs effectively protect against
aspirin and nonsteroidal anti-inflammatory drug (NSAID)-
induced PUD and PUB.1,2 However, no medication is com-
pletely devoid of adverse effects, and three major concerns
with PPI therapy have been raised, including the risks of
pneumonia, enteric infections, and bone fracture.
Mechanistically, whether PPI use has any effect on the risk
of pneumonia in patients remains unclear. PPIs enable the
proliferation of microorganisms in the stomach that could
reflux back and be aspirated, which could increase the risk of
pneumonia.3 Two meta-analysis studies evaluated the associ-
ation between PPI therapy and the occurrence of hospital- and
community-acquired pneumonia in case-control and observa-
tional studies.4,5 They found a positive association between
PPI therapy and pneumonia (odds ratio [OR] ~1.27e1.36).
However, the studies were heterogeneous, and also indicated
that the association with pneumonia was much stronger if a
PPI was prescribed within the past 7 days than if the drugs
were prescribed within the past 30e180 days.6,7 It seems that
protopathic bias remains the most likely explanation for this
finding. In observational studies, the modest associations
between a risk factor and a disease are usually attributable to
bias or confounding and are rarely the result of a causal effect.
The association between PPI therapy and pneumonia might
also be an example of this phenomenon. Two systematic
reviews investigating the association between PPI therapy and
pneumonia in randomized control trials (RCTs) did not find
any statistically significant effects.6,7
One of the main roles of gastric acid is to kill bacteria in
food that could be potential pathogens while we eat. A sys-
tematic review of observational studies from 10,430 subjects
found a significant association between PPI therapy and the
risk of enteric infection cause by Salmonella and Campylo-
bacter species (OR: 3.33).8 The potential association
between Clostridium difficile-associated diarrhea (CDAD)
and PPI therapy is complex. A systematic review withoutx.doi.org/10.1016/j.jcma.2015.08.003
901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Asseach paper's adjusting for potential confounding factors
found an association between CDAD and PPI therapy, but the
OR (2.05) was lower than for other enteric infections.8 It is
possible that PPI therapy alters the composition of the gut
bacterial flora, which would provide an environment enabling
toxigenic strains of CD to flourish. Regarding gut
micropathogen-associated disease while taking PPIs, a
population-based case-control study showed that PPI therapy
significantly increased the risk of cryptogenic liver abscess.9
A meta-analysis study revealed that PPI therapy was asso-
ciated with a greater risk of spontaneous bacterial peritonitis
(SBP) in hospitalized patients with cirrhosis.10 Otherwise,
Ho's11 study did not find that PPI therapy increased the risk of
colonic diverticulitis.
Systematic reviews and meta-analyses including five
cohort and six case-control studies concluded that patients on
PPI therapy had a significantly increased risk of hip fractures
(OR: 1.25) and vertebral fractures (OR: 1.50).12 No evidence
supported an association between PPI therapy and the risk of
wrist or forearm fracture. However, the observed statistically
significant association cannot be interpreted as proof of cau-
sality, because the association could have resulted from
residual or unmeasured confounding, as was described for the
association between pneumonia and PPI therapy. The most
commonly proposed mechanism is that PPI therapy, by
decreasing the absorption of ingested calcium, leads to a
negative calcium balance and eventually to bone loss and
osteoporosis.13 Two RCTs that utilized more reliable methods
(dual stable isotope method) than the previous studies showed
no evidence of an effect of PPI use on the absorption of
calcium under customary physiological conditions in healthy
young volunteers and postmenopausal women, respec-
tively.14,15 In brief, there is no persuasive evidence that the
association is causal, although this can never be excluded as a
possibility.16
In conclusion, although the possibility of adverse events
attributable to PPI therapy cannot be excluded, including
pneumonia, enteric infections, CDAD, SBP, and bone fracture,
it is important that PPIs are only prescribed to patients who
may benefit from them such as patients with reflux esoph-
agitis, PUD, PUB post endoscopic therapy, and patients with a
high risk of PUB when taking antiplatelets or NSAIDs.ociation. All rights reserved.
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